Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 5.02B |
| Revenue (ttm) | 92.29M |
| Net Income (ttm) | -59.29M |
| Shares Out | 198.35M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $24.89 |
| Previous Close | $24.36 |
| Change ($) | 0.53 |
| Change (%) | 2.18% |
| Day's Open | 24.85 |
| Day's Range | 24.60 - 26.34 |
| Day's Volume | 2,483,080 |
| 52-Week Range | 3.26 - 53.69 |
MENLO PARK, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:
Pacific Biosciences' (PACB) revenues grow in both its segments during the first quarter.
The company released its first-quarter earnings report, but that doesn't tell the whole story.
Shares of Pacific Biosciences (NASDAQ:PACB) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 4600.00% over the past year to ($0.45), which we...
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.
MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, announced today that Dr...
MENLO PARK, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of g...
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its first quarter 2021 financial results ...
We're really excited that these genomics companies, says Ark's Simon Barnett
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
These two disruptive companies have long growth runways ahead of them.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
Pacific Biosciences' (PACB) Sequel II HiFi sequencing gets utilized by LabCorp to detect SARS-COV-2 variants in the United States.
The stock price of Pacific Biosciences of California a biotechnology company that develops gene sequencing systems, has seen a solid 27% rise over the last ten trading days, though it's down 4% over the...
Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S. Labcorp Using PacBio's HiFi Sequencing to Detect SARS-CoV-2 Variants in the U.S.
Will SoftBank Group Corp.'s (SFTBY) huge investment in Pacific Biosciences of California Inc.(NASDAQ:PACB) turn out to be another home run for the Japanese conglomerate or will it be a swing and a miss ...
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...
The pandemic didn't weigh on the genetic sequencing systems company nearly as much as earlier in 2020.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -102.33% and -0.05%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Pacific Biosciences (NASDAQ:PACB) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 0.00% over the past year to $0.37, which beat...
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2020. Re...
Pacific Biosciences is getting an investment from a holding company.
MENLO PARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today an...
SoftBank Group Corp (OTCMKTS: SFTBY) will reportedly invest $900 million into Pacific Biosciences of California Inc (NASDAQ: PACB), according to the Wall Street Journal, which comes on top of around 6% ...
Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.
On Wednesday, February 10, Pacific Biosciences (NASDAQ:PACB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...
A new leadership team is betting that it can make long-read genome sequencing more competitive.
MENLO PARK, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...
MENLO PARK, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its fourth quarter 2020 financial results ...
After a large 13x rise since the March 23 levels of last year, at the current price of around $36 per share we believe Pacific Biosciences of California stock, a biotechnology company that develops gene...
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.
New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care New platform expected to make whole genome sequencing significantly ...
MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read seque...
MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced una...
MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of...
Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation Seven new Sequel IIe Systems...
Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.
Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.
MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of ge...
BioCardia (NASDAQ: BCDA) shares are trading higher. The company said it anticipates data safety monitoring board verbal feedback by the end of Dec. 15 for its pivotal Phase 3 CardiAMP Heart Failure Trial.
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of its solid prospects.
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonuclease... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 27, 2010 |
| Stock Exchange NASDAQ | Ticker Symbol PACB |
Analyst Forecasts
According to 5 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is 51.50, which is an increase of 106.91% from the latest price.